Pharmaceuticals – India’s Drug Market Shows Strong Growth Ahead of US Tariff Shift
Pharmaceuticals –India’s pharmaceutical industry is witnessing robust domestic expansion as it prepares for a two-year transition period before the United States introduces higher tariffs on imported generic medicines. A recent report by Equirus Securities suggests that strong demand across multiple therapy segments, coupled with healthy product launches, has strengthened the industry’s position despite upcoming changes in international trade policies.
US Tariff Timeline Provides Temporary Relief
The positive domestic outlook comes after US President Donald Trump announced that imported generic medicines will remain exempt from tariffs for two years beginning August 1, 2026. Following this transition period, tariffs are expected to increase gradually, reaching as much as 200 percent over the next two years. The temporary exemption gives pharmaceutical exporters additional time to adapt their business strategies before the proposed duties take effect.
Indian Pharmaceutical Market Records Best Monthly Performance
According to the Equirus Securities report, the Indian Pharmaceutical Market (IPM) delivered its strongest monthly growth in more than two years during June. The market expanded by 16 percent compared with the same month last year, while growth for the first quarter of FY27 reached 13.5 percent year-on-year.
The report noted that the latest performance highlights the continued strength of India’s domestic formulations business. Consistent demand from consumers, combined with improving market conditions, has helped sustain growth even as the global trade environment remains uncertain.
Multiple Factors Drive Industry Expansion
Equirus Securities attributed the strong performance to improvements across all major growth indicators. Medicine volumes increased by 3.4 percent, reflecting higher consumption across the country. Price-led growth contributed 4.6 percent, while newly launched products added another 3.1 percent to overall market expansion.
The combination of rising sales volumes and an active pipeline of new medicines indicates that pharmaceutical companies are benefiting from both stronger consumer demand and continued innovation. The report suggested that these trends have supported steady momentum across the sector.
Growth Seen Across Every Major Therapy Segment
The report also highlighted that all ten leading therapy categories registered double-digit growth during June, demonstrating broad-based expansion rather than reliance on a few product groups.
Cardiac and anti-diabetic medicines emerged as the strongest-performing therapy areas. Demand for diabetes treatments continued to rise, with anti-diabetic drugs becoming the country’s third-largest therapy segment. The report linked this growth to increasing adoption of GLP-1-based therapies, which have gained wider acceptance in diabetes management.
Meanwhile, medicines used for chronic illnesses maintained their leadership in market performance, while therapies for acute conditions also showed noticeable improvement. This balanced growth suggests that demand is strengthening across different healthcare needs.
Leading Drugmakers Outperform Overall Market
Several major pharmaceutical companies reported growth that exceeded the broader industry average during June. Torrent Pharma and Zydus recorded growth of around 20 percent, placing them among the strongest performers.
Other leading companies, including Cipla, Dr. Reddy’s Laboratories, Lupin, and Sun Pharma, also delivered growth above the overall market rate. According to the report, the same trend continued through the first quarter of FY27, with companies focused on chronic therapies and volume-driven business models maintaining a competitive advantage.
Domestic Market Remains Resilient
Equirus Securities concluded that India’s pharmaceutical sector is entering a period of changing global trade conditions from a position of strength. Healthy domestic demand, expanding product portfolios, and consistent growth across multiple therapy categories have reinforced the resilience of the country’s formulations market.
While future US tariff changes may reshape export dynamics over the coming years, the report indicates that the strong performance of the domestic pharmaceutical market provides a solid foundation for the industry as it prepares for evolving international trade policies.